Librela is the first and only monthly injectable anti-nerve growth
factor (NGF) monoclonal antibody (mAb) therapy for dogs with
osteoarthritis (OA) pain.

▪Effectively controls canine OA pain with a monthly injection
▪Approved as safe and is metabolized and eliminated like naturally
occurring antibodies, with minimal involvement of the liver or kidneys
▪Works differently than NSAIDs by reducing NGF effects, a key factor in
canine OA pain
▪Reduced canine OA pain, which led to increased activity and improved
quality of life